Posted On: 03/05/2014 9:12:24 AM
Post# of 145202
If $NVLX - Nuvilex's late-phase clinical trials can continue to outperform Celgene's therapy, then the company's treatment will likely be the new "gold standard" for the disease -- a designation that earned Eli Lilly's drug Gemzar more than $10 billion when it was the "gold standard" for advanced inoperable pancreatic cancer. It is numbers like this that make it clear why so many have remained patient with their Nuvilex investment, and we haven't even begun to discuss the company's future in diabetes! http://www.stockwatch.com/News/Item.aspx?bid=...p;region=U
(0)
(0)
